Japan Medical Dynamic Marketing, Inc. AI Stock Analysis
Want to see JP:7600 full AI Analyst Report?
Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis
Japan Medical Dynamic Marketing, Inc.
(TSE/TYO:7600)
Japan Medical Dynamic Marketing scores near the bottom of the range, driven primarily by severe fundamental deterioration: profitability has collapsed across gross, operating and net margins, FY2025 ended in a net loss, revenue is projected to decline in FY2026, and free cash flow has turned deeply negative while debt has nearly quadrupled. Technicals compound the concern, with the share price trading well below all major moving averages and momentum indicators at extremely depressed levels. A 3.76% dividend yield and a still-solid equity ratio provide some support, but with negative earnings and negative free cash flow, dividend sustainability and a near-term turnaround remain uncertain. Investors should look for evidence that the heavy investment cycle is translating into margin and cash flow recovery before the risk profile improves.
Japan Medical Dynamic Marketing, Inc. (7600) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.06B
- Dividend Yield
- 5.76%
- Average Volume (3M)
- 376.84K
- Price to Earnings (P/E)
- -4.6
- Beta (1Y)
- 1.06
- Revenue Growth
- -8.68%
- EPS Growth
- -75.03%
- Country
- Japan
- Employees
- 539
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model
Company Description
Japan Medical Dynamic Marketing, Inc. (JMDM) engages in the development, production, importation, and distribution of medical instruments throughout Japan and the United States. Its product portfolio features a variety of trauma devices, including su...
How the Company Makes Money
The company primarily generates revenue through the sale and distribution of medical devices and related healthcare products to customers such as hospitals, clinics, and other medical institutions. Revenue is typically recognized from product sales (...
Japan Medical Dynamic Marketing, Inc. Financial Statement Overview
Summary
Financial health has deteriorated sharply. The income statement (score 28) shows gross margins collapsing from ~68% to ~53%, EBIT margins down to 2.4%, a net loss in FY2025 and a projected -4.3% revenue decline in FY2026. Cash flow (score 25) is the weakest link: operating cash flow fell over 93% to ¥206M and free cash flow is deeply negative at -¥1.75B as capex far outstrips earnings. The balance sheet (score 52) is the relative bright spot, with a solid ~71% equity ratio and growing equity, but total debt has nearly quadrupled in two years to ¥5.9B and ROE has fallen to roughly 1%, indicating investments are being funded by borrowing rather than internal cash generation.
Income Statement
28NegativeBalance Sheet
52NeutralCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.32B | 23.92B | 25.11B | 23.18B | 21.31B | 19.19B |
| Gross Profit | 12.00B | 12.74B | 15.65B | 14.76B | 13.99B | 12.99B |
| EBITDA | 1.62B | 2.19B | 1.40B | 3.27B | 3.35B | 4.21B |
| Net Income | -220.55M | 263.14M | -461.80M | 1.27B | 1.42B | 2.14B |
Balance Sheet | ||||||
| Total Assets | 35.38B | 35.68B | 33.83B | 31.49B | 29.43B | 27.34B |
| Cash, Cash Equivalents and Short-Term Investments | 2.56B | 3.11B | 3.18B | 2.32B | 2.80B | 2.59B |
| Total Debt | 6.63B | 5.87B | 3.29B | 1.49B | 1.87B | 1.85B |
| Total Liabilities | 10.55B | 10.25B | 9.09B | 5.88B | 6.14B | 5.85B |
| Stockholders Equity | 24.81B | 25.40B | 24.68B | 25.51B | 23.16B | 21.39B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.75B | -504.10M | 302.45M | 870.67M | 1.53B |
| Operating Cash Flow | 0 | 205.55M | 1.05B | 2.10B | 2.19B | 3.11B |
| Investing Cash Flow | 0 | -2.00B | -1.67B | -1.80B | -1.48B | -1.75B |
| Financing Cash Flow | 0 | 1.65B | 1.49B | -840.71M | -514.78M | -1.29B |
Japan Medical Dynamic Marketing, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Negative. The current price of 261.00 is below the 20-day moving average (MA) of 427.20, below the 50-day MA of 552.90, and below the 200-day MA of 664.53, indicating a bearish trend. The MACD of -90.20 indicates Positive momentum. The RSI at 11.61 is Positive, neither overbought nor oversold. The STOCH value of 8.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7600.
Japan Medical Dynamic Marketing, Inc. Peers Comparison
Overall Rating
JP:667882Outperform
JP:684963Neutral
JP:652361Neutral
JP:454950Neutral
JP:777948Neutral
JP:760038Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | JPY 18.02B | 12.03 | ― | 6.10% | 17.11% | 23.02% | |
| 63Neutral | JPY 249.68B | 20.61 | ― | 2.10% | -0.18% | -33.38% | |
| 61Neutral | JPY 164.51B | 11.06 | 8.71% | 3.25% | 2.74% | 145.33% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | JPY 75.00B | 39.80 | ― | 2.55% | 3.92% | -52.01% | |
| 48Neutral | JPY 35.89B | 256.25 | 0.34% | ― | -7.45% | ― | |
| 38Underperform | JPY 7.77B | -4.61 | ― | 5.76% | -8.68% | -75.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 261.00 | -205.88 | -44.10% | |
| JP:7779 | CYBERDYNE | 162.00 | -9.00 | -5.26% | |
| JP:6523 | PHC Holdings Corp. | 1236.00 | 278.26 | 29.05% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2235.00 | -57.25 | -2.50% | |
| JP:6678 | Techno Medica Co., Ltd. | 2118.00 | 234.98 | 12.48% | |
| JP:6849 | Nihon Kohden Corporation | 1514.50 | -3.68 | -0.24% |
Japan Medical Dynamic Marketing, Inc. Corporate Events
TSE Approves Japan Medical Dynamic Marketing’s Move to Standard Market
Japan Medical Dynamic Marketing, Inc. is listed on the Tokyo Stock Exchange under securities code 7600.The Tokyo Stock Exchange approved the company’s market-segment change from the Prime Market to the Standard Market on November 20, effective Novemb...
Japan Medical Dynamic Marketing Outlines First-Half Results Briefing Agenda
Japan Medical Dynamic Marketing, Inc. provided an agenda for its financial results briefing covering the interim period of the fiscal year ending March 2027. The agenda covers first-half consolidated sales and income, product-category sales reviews i...
Japan Medical Marketing Announces Management Cuts and Business Improvement Plan
Japan Medical Dynamic Marketing operates in the orthopedic medical-device industry, supplying trauma and spine products in Japan and the United States. Its market focus includes priority customers, new product adoption and recovery of procedure volum...
Japan Medical Dynamic Marketing Reports Interim Loss and Withdraws Dividend
Japan Medical Dynamic Marketing is a medical-device company focused on orthopedic products, including joint-replacement systems, with operations in Japan and the United States. Its business is exposed to hospital adoption trends, product competitiven...
Japan Medical Dynamic Marketing Swings to Interim Loss as Sales Decline
Japan Medical Dynamic Marketing, Inc. is a Tokyo-listed medical-device marketing company, although the release does not detail its product portfolio or market focus. For the six months ended September 30, 2026, consolidated sales fell 10.1% year over...
Japan Medical Dynamic Marketing Cuts U.S. Workforce to Bolster Profitability
Japan Medical Dynamic Marketing, Inc. has launched cost-cutting measures at its U.S. subsidiary Ortho Development Corporation, driven by declining net sales and the need to strengthen its earnings base. The subsidiary will undergo an organizational r...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
